362 related articles for article (PubMed ID: 28222635)
21. The Predictive Role of Serum Cystatin C Levels in Polycystic Ovary Syndrome in Adolescents.
Çınar M; Aksoy RT; Güzel Aİ; Tokmak A; Çandar T; Taşçı Y
J Pediatr Adolesc Gynecol; 2016 Aug; 29(4):353-6. PubMed ID: 26740281
[TBL] [Abstract][Full Text] [Related]
22. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
[TBL] [Abstract][Full Text] [Related]
23. Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile.
Sahin Ersoy G; Altun Ensari T; Vatansever D; Emirdar V; Cevik O
Gynecol Endocrinol; 2017 Feb; 33(2):119-123. PubMed ID: 27690684
[TBL] [Abstract][Full Text] [Related]
24. The relationship between retinol-binding protein 4 levels, insulin resistance, androgen hormones and polycystic ovary syndrome.
Mellati AA; Sharifi F; Sajadinejad M; Sohrabi D; Mazloomzadeh S
Scand J Clin Lab Invest; 2012 Feb; 72(1):39-44. PubMed ID: 22023042
[TBL] [Abstract][Full Text] [Related]
25. Several Circulating Biomarkers for PCOS Diagnosis.
Luo P; Zhang C; He Y; Yang G; Liu H; Li L
Exp Clin Endocrinol Diabetes; 2021 Oct; 129(10):705-712. PubMed ID: 31683329
[TBL] [Abstract][Full Text] [Related]
26. Adropin in women with polycystic ovary syndrome.
Kuliczkowska-Płaksej J; Mierzwicka A; Jończyk M; Stachowska B; Urbanovych A; Bolanowski M
Endokrynol Pol; 2019; 70(2):151-156. PubMed ID: 30480749
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of betatrophin concentrations in childhood and adolescent obesity and insulin resistance.
Wu S; Gao H; Ma Y; Fu L; Zhang C; Luo X
Pediatr Diabetes; 2016 Feb; 17(1):53-60. PubMed ID: 25413012
[TBL] [Abstract][Full Text] [Related]
28. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome.
Yucel A; Noyan V; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):81-6. PubMed ID: 16337726
[TBL] [Abstract][Full Text] [Related]
29. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
30. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
31. [Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients].
Zhang HY; Zhang YF; Han YK; Xue FX; Zhao XH; Zhang XL
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):19-23. PubMed ID: 22455688
[TBL] [Abstract][Full Text] [Related]
32. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
33. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
Wan DH; Fan P; Bai H; Song Q; Liu HW
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
[TBL] [Abstract][Full Text] [Related]
34. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters.
Demirci H; Yilmaz M; Ergun MA; Yurtcu E; Bukan N; Ayvaz G
Gynecol Endocrinol; 2010 May; 26(5):348-55. PubMed ID: 20388053
[TBL] [Abstract][Full Text] [Related]
35. Preptin in women with polycystic ovary syndrome.
Mierzwicka A; Kuliczkowska-Plaksej J; Kolačkov K; Bolanowski M
Gynecol Endocrinol; 2018 Jun; 34(6):470-475. PubMed ID: 29374985
[TBL] [Abstract][Full Text] [Related]
36. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of biochemical, endocrine, and metabolic biomarkers for the early diagnosis of polycystic ovary syndrome among non-obese Saudi women.
Daghestani MH
Int J Gynaecol Obstet; 2018 Aug; 142(2):162-169. PubMed ID: 29745981
[TBL] [Abstract][Full Text] [Related]
38. Serum betatrophin levels are significantly increased in obese patients compared to lean patients regardless to the presence of PCOS.
Keyif B; Goksever Celik H; Karamustafaoglu Balci B; Mehves Celebi M; Ozaltin S; Takmaz O; Buyru F; Baştu E
Gynecol Endocrinol; 2020 Aug; 36(8):678-681. PubMed ID: 32129695
[TBL] [Abstract][Full Text] [Related]
39. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
40. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease.
Fenkci V; Fenkci S; Yilmazer M; Serteser M
Fertil Steril; 2003 Jul; 80(1):123-7. PubMed ID: 12849813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
